Humana Inc.
HUM
Market Cap$37.53B
Close$
Earnings Call Q4 2023
January 25, 2024 - AI Summary
Humana reported disappointing results for the fourth quarter of 2023, with higher-than-expected utilization trends impacting the Medicare Advantage sector.
The company expects the higher costs seen in the fourth quarter to persist throughout 2024 and has prudently assumed this in their initial outlook for adjusted EPS of approximately $16 for 2024.
Looking ahead to 2025, Humana is evaluating Medicare Advantage pricing actions and expects earnings growth in other lines of business, as well as ongoing productivity and trend mitigation initiatives. They anticipate $6 to $10 of adjusted EPS growth in 2025, with any outperformance in 2024 being additive to this initial outlook.
Exclusive for Stockcircle Pro members
Sign up
$339.34
8% upside
Current Fair Value
8% upsideUndervalued by 8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $37.53 Billion |
|---|---|
| Enterprise Value | $51.07 Billion |
| Dividend Yield | $3.5282 (1.13%) |
| Earnings per Share | $20.0 |
| Beta | 0.0 |
| Outstanding Shares | 120,500,635 |
| Avg 30 Day Volume | 1,993,869 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 15.08 |
|---|---|
| PEG | -37.51 |
| Price to Sales | 0.35 |
| Price to Book Ratio | 2.36 |
| Enterprise Value to Revenue | 0.47 |
| Enterprise Value to EBIT | 14.76 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.27 |
| Debt to Equity | 0.84 |
Revenue Sources
No data
ESG Score
No data
About Humana Inc.
CEO: Bruce Broussard